Status:
WITHDRAWN
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Lead Sponsor:
Rajan Saggar
Collaborating Sponsors:
Actelion
Conditions:
Pulmonary Arterial Hypertension
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no si...
Detailed Description
The purpose of this study was to evaluate bosentan in the setting of exercise or resting pulmonary hypertension in patients with underlying pulmonary fibrosis.
Eligibility Criteria
Inclusion
- Idiopathic Pulmonary Fibrosis referred for lung transplantation
- Minimum 50 meter 6 minute walk distance
- No significant underlying liver disease
Exclusion
- Significant liver disease or cirrhosis
- non ambulatory
- previous adverse reaction/allergy to Bosentan
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00625469
Start Date
October 1 2007
End Date
December 1 2009
Last Update
March 6 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
David Geffen School of Medicine UCLA
Los Angeles, California, United States, 90095-1690
2
Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
Los Angeles, California, United States, 90095-1690